



COPY OF PAPERS
ORIGINALLY FILED

Docket No. 13761-7024

#10/ K.T.
9/8
1653
pfe
A

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: May 20, 2002 Name of Person Certifying: _____
Printed Name: Lae Barrett

TECH CENTER 1600/2900

JUN 03 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lin, et al. Assignee: University of Southern California
Filing Date: 08/01/2001 Examiner: Unassigned
Serial No.: 09/920,342 Group Art Unit: 1653
Title: **GENE SILENCING USING MRNA-CDNA HYBRIDS**

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please enter the following Preliminary Amendment in the above-identified patent application.

IN THE CLAIMS

Please ADD the following new dependent claims:

- A¹
46. (New) The method of claim 19, wherein the nucleotide analog is selected from the group consisting of uracil, inosine, xanthine, hypoxanthine, labeled nucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphothio-linked nucleotide, morpholino nucleotide and peptide nucleic acid (PNA).
47. (New) The method of claim 19, wherein the nucleotide analog is a ribonucleotide.
48. (New) The method of claim 19, wherein the nucleotide analog is a deoxyribonucleotide.